BASF's Oil-Price Tailwind Meets a Wall of Analyst Caution

A softer crude market handed BASF a fresh cost argument this week, but the chemicals group's shares closed well short of the price targets analysts have set, a reminder that cheaper feedstock is not the same thing as booked profit.

The stock finished Tuesday at €54.25, up 1.9%, after Brent fell in the wake of the US midterm elections. Lower energy and input costs could ease pressure on BASF's margins, yet no direct link between the oil move and the share gain has been established. The potential saving is industry backdrop, not a company earnings release — and certainly not proof that any savings have been realized.

That distinction matters for anyone weighing the stock. Betting on the cost opportunity means betting on possible additional relief. Assuming higher profits are already in hand means getting ahead of an effect whose size cannot be derived from the oil price alone.

The Clean Number Is the One to Watch

The real test is EBITDA before special items. Roughly a week ago BASF reported a 15% rise in that measure to €1.6 billion for the third quarter of 2026 and lifted its earnings guidance once again. Revenue for the same period climbed 14% to €16.4 billion, with the company saying all core segments contributed.

That points to a broad-based improvement rather than a single bright spot. Even so, earnings deserve more weight than the top line: only they will show whether cheaper inputs actually reach the bottom line. A falling oil price, on its own, answers nothing.

For the full year 2026, BASF now expects EBITDA before special items of €7.4 billion to €7.8 billion.

Analysts Agree on Little Beyond the Direction

LBBW raised its target to €57 from €56 on Tuesday while keeping a "Hold" rating — a combination that signals slightly friendlier valuation without unqualified optimism. Bernstein Research moved the other way on 29 October, trimming its target to €59 from €61 but sticking with "Outperform." UBS stayed at "Neutral" with a €55 target that same day, with analyst Joshua Spector revising his estimates after the quarterly report.

The spread of views argues against reading the recent numbers as unreservedly bullish. The risk for investors is pricing a favorable cost impulse in full before its effect becomes visible.

Capital returns are running in parallel. BASF reported on Monday the buyback of 355,128 of its own shares, purchased from 26 through 30 October under its ongoing repurchase program. Such moves are no substitute for operational improvement, but they form part of the capital-markets policy investors can weigh alongside the business result.

Evonik Talks Hit a Wall

The possible Evonik transaction remains a question of capital discipline. CEO Markus Kamieth stressed roughly a week ago that BASF will not overpay for Evonik and will pursue a deal only if it creates value for BASF shareholders. Evonik's management declined negotiations on 30 October, offering only a confidential, purely informational exchange; BASF responded with bafflement. No takeover has been agreed and no earnings effect is assured.

Elsewhere the company is building out other parts of the business. On Tuesday BASF and ParagonCorp signed a letter of intent to collaborate on science-backed cosmetic innovations — a different field from the renewable surfactants BASF is also expanding. On 27 October the company started up expanded alkylpolyglucoside capacity in Cincinnati, Ohio, which it says strengthens regional supply of renewable surfactants. A Capital Markets Day is scheduled for 24 November in Ludwigshafen, where Agricultural Solutions is among the businesses to be presented.

February Brings the Next Reckoning

So long as cheaper inputs support operations and the core segments keep growing, further earnings improvement remains a plausible scenario. Should the cost benefit reverse or momentum fade, that foundation would weaken.

BASF's next scheduled report, on 26 February 2027, offers a concrete checkpoint: how operations have progressed, and what the company says about the road ahead. The decision for investors turns less on Tuesday's share move than on the durability of earnings — the oil decline opens an opportunity, but only the business can confirm it.